K G Waller1, R W Shaw. 1. Academic Department of Obstetrics and Gynaecology, Royal Free Hospital, London, United Kingdom.
Abstract
OBJECTIVE: To determine the long-term recurrence rate of endometriosis after treatment with gonadotropin-releasing hormone analogues (GnRH-a). DESIGN: A historical prospective study. SETTING: Royal Free Hospital, London, a tertiary referral center for the treatment of endometriosis. PATIENTS: One hundred thirty patients with endometriosis had treatment with GnRH-abuserelin acetate, goserelin, and nafarelin acetatebetween the years 1985 and 1987. Patients no longer being followed in the gynecology clinic were sent a questionnaire to determine their state of health. Information was also requested from the patient's general practitioner. MAIN OUTCOME MEASURES: The cumulative recurrence rate for the fifth year after treatment ended was 53.4%. RESULTS: Patients with a higher disease stage at the outset were more likely to experience recurrence and experience it earlier than patients with minimal disease. Fifth-year recurrence rates were 36.9% for minimal disease and 74.4% for severe disease. The change in endometriosis stage classification scores at second-look laparoscopy for those patients whose disease recurred after treatment was not significantly different from those whose disease did not recur during the study period. CONCLUSIONS:Patients with endometriosis treated withGnRH-a are highly likely to suffer a recurrence of their disease, particularly if their disease is severe at the outset.
RCT Entities:
OBJECTIVE: To determine the long-term recurrence rate of endometriosis after treatment with gonadotropin-releasing hormone analogues (GnRH-a). DESIGN: A historical prospective study. SETTING: Royal Free Hospital, London, a tertiary referral center for the treatment of endometriosis. PATIENTS: One hundred thirty patients with endometriosis had treatment with GnRH-a buserelin acetate, goserelin, and nafarelin acetate between the years 1985 and 1987. Patients no longer being followed in the gynecology clinic were sent a questionnaire to determine their state of health. Information was also requested from the patient's general practitioner. MAIN OUTCOME MEASURES: The cumulative recurrence rate for the fifth year after treatment ended was 53.4%. RESULTS:Patients with a higher disease stage at the outset were more likely to experience recurrence and experience it earlier than patients with minimal disease. Fifth-year recurrence rates were 36.9% for minimal disease and 74.4% for severe disease. The change in endometriosis stage classification scores at second-look laparoscopy for those patients whose disease recurred after treatment was not significantly different from those whose disease did not recur during the study period. CONCLUSIONS:Patients with endometriosis treated with GnRH-a are highly likely to suffer a recurrence of their disease, particularly if their disease is severe at the outset.
Authors: Sun-Wei Guo; Lone Hummelshoj; David L Olive; Serdar E Bulun; Thomas M D'Hooghe; Johannes L H Evers Journal: Hum Reprod Date: 2009-03-04 Impact factor: 6.918
Authors: Fadi Abushahin; Kara N Goldman; Elizabeth Barbieri; Magdy Milad; Alfred Rademaker; Serdar E Bulun Journal: Fertil Steril Date: 2011-08-24 Impact factor: 7.329
Authors: S Landi; L Mereu; U Indraccolo; R Favero; A Fiaccavento; R Zaccoletti; R Clarizia; F Barbieri Journal: JSLS Date: 2009 Oct-Dec Impact factor: 2.172
Authors: Nadja Tariverdian; Theoharis C Theoharides; Friederike Siedentopf; Gabriela Gutiérrez; Udo Jeschke; Gabriel A Rabinovich; Sandra M Blois; Petra C Arck Journal: Semin Immunopathol Date: 2007-06 Impact factor: 9.623